Advances in development of 64CuCl2 radiotracer for diagnostic imaging of copper metabolism disorders with PET
10.3760/cma.j.issn.2095-2848.2019.06.011
- VernacularTitle: 64CuCl2作为正电子示踪剂用于Cu代谢异常疾病诊断的研究进展
- Author:
Huawei CAI
1
,
2
;
Fang XIE
1
,
3
;
Fangyu PENG
1
Author Information
1. Department of Radiology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
2. Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu 610041, China
3. PET Center, Huashan Hospital, Fudan University, Shanghai 200235, China
- Publication Type:Review
- Keywords:
Copper radioisotopes;
Positron-emission tomography;
Copper;
Metabolic diseases;
Trends
- From:
Chinese Journal of Nuclear Medicine and Molecular Imaging
2019;39(6):370-373
- CountryChina
- Language:Chinese
-
Abstract:
Development of new radiopharmaceuticals is crucial for the advance of nuclear medicine and molecular imaging. In recent years, significant progress has been made in the development of radiopharmaceuticals based on radioactive metal nuclides such as 64Cu. Copper is a transition metal element necessary for human physiology. Disorders of copper metabolism not only cause hereditary Wilson disease and Menkes disease, but also play an important role in the development of malignant tumors. In addition to radiolabeling for probes, 64Cu can be used for PET diagnostic imaging of copper metabolism disorders. 64CuCl2 is a useful radiotracer that can be used to track the dynamic flow of copper ions in human body copper metabolism by PET imaging. In recent years, many preclinical and clinical studies of 64CuCl2 radiotracer have achieved good results, and have attracted a lot of attention in the field of nuclear medicine and molecular imaging. In this article, the progress in the development of 64CuCl2 as a radiotracer for PET diagnostic imaging of hereditary copper metabolism disorders and copper hypermetabolic tumors is reviewed, and further research studies and potential clinical application of 64CuCl2 PET/CT imaging is prospected.
